Floatz logo

BANOXANTRONE DIHYDROCHLORIDE

Solid Malignancies

NovaceaSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Solid Malignancies cohort.

Asset / SponsorPhaseRating
ROBLITINIB
Novartis Pharmaceuticals
Phase 1/2CCC
ct7439 capsules
Carrick Therapeutics Limited
Phase 1/2CC
Gimatecan
Sigma-Tau Research, Inc.
Phase 1CC
7-t-butyldimethylsilyl-10-hydroxycamptothecin
University of Kentucky
Phase 1CC
Vistusertib
AstraZeneca
Phase 1CC

View all 13 →

Same molecule, other indications

BANOXANTRONE DIHYDROCHLORIDE is also rated in:

Non-Hodgkin's LymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
Glioblastoma MultiformeDormant
CC
Indicative ·
45 / 100
View asset →
Chronic Lymphocytic LeukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →